Movano, Inc. — FY 2021 Form 10-K
Filing identity: The supplied filing is for Movano, Inc. (Nasdaq: MOVE), not Corvex, Inc. It covers the fiscal year ended December 31, 2021; it does not report a separate Q4 financial statement.
Business context and reporting period
Movano is a development-stage health technology company developing RF-based wearable sensors, mobile software and cloud services. Its first planned product is a smart ring aimed at women. The company had not launched a commercial product or generated revenue by year-end. The ring’s initial version was not expected to include FDA-cleared features; future versions are intended to pursue medical-device clearance, including for glucose and blood-pressure monitoring.
Financial performance and position
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $13.4 million | $8.4 million |
| General and administrative expense | $6.4 million | $2.7 million |
| Total operating expenses / operating loss | $19.8 million | $11.1 million |
| Net loss | $21.8 million | $13.0 million |
| Net loss attributable to common stockholders | $24.3 million | $21.9 million |
| Basic and diluted loss per share | $0.92 | $6.85 |
| Net cash used in operating activities | $16.2 million | $10.7 million |
At December 31, 2021, cash and cash equivalents were $17.7 million and short-term investments were $15.9 million, or $33.6 million combined. Total assets were $36.3 million; total liabilities were $3.5 million. No funded convertible-note balance remained: notes and accrued interest converted to common stock at the IPO. The filing reports no revenue, so operating margins are not meaningful.
FY 2021 investing cash outflow was $16.7 million, principally reflecting purchases of short-term investments; financing cash inflow was $44.8 million, largely IPO proceeds. The company raised approximately $44.3 million net in the IPO according to the financial-statement note. The cash-flow statement reports $44.8 million of net IPO proceeds, so the filing contains differing presentations that investors may wish to reconcile.
Material changes versus the prior comparable period
- Net loss increased to $21.8 million from $13.0 million. R&D expense rose 60% and G&A expense rose 133%, which management attributed primarily to company growth and increased activity.
- Operating cash use increased to $16.2 million from $10.7 million.
- Cash and short-term investments rose to $33.6 million, following the 2021 IPO. Preferred stock and convertible notes converted into common stock; year-end liabilities fell from $15.1 million in 2020 to $3.5 million in 2021.
- Accumulated deficit reached $64.8 million. Common shares outstanding increased to 32.8 million from 6.4 million at year-end 2020.
Outlook, risks and unusual items
- Management said year-end cash and short-term investments were expected to fund projected operating requirements for at least 12 months, but would not be enough to complete product development and commercialization. The company expects significant expenses and increasing losses for several years and anticipates needing additional financing.
- Development milestones included completion of a single-chip design tapeout in 2021 and a 110-participant blood-pressure study. A 10-participant glucose pilot study was completed in February 2022. These studies were intended to refine algorithms; the filing says no studies had yet demonstrated commercial-level accuracy for glucose or blood pressure.
- Key risks include technical and clinical validation, FDA and FCC requirements, manufacturing and commercialization dependencies, competition, future financing and dilution, and continued operating losses. The company had no current OEM, reseller or distributor relationship, while expecting to rely on partners for aspects of design, manufacturing and sales.
- The company recognized $0.4 million of PPP loan forgiveness in 2021. Other expense included a $1.6 million noncash increase in warrant-liability fair value; those liability-classified warrants were reclassified to equity in connection with the IPO.
- Management concluded disclosure controls were ineffective at year-end and identified a material weakness in the design and operation of financial close and reporting controls, including account reviews and certain IT general controls. No resulting financial-statement misstatement was identified. The auditor issued an unmodified opinion on the financial statements, but did not audit internal control effectiveness.
- The filing reports no material pending legal proceeding. Operating-lease minimum payments totaled $490,000 as of year-end.
Most important facts for investors to verify
- Confirm the issuer and period: the document is Movano, Inc.’s FY 2021 10-K, not a Corvex filing or a standalone Q4 report.
- Track cash consumption, investment liquidity and the timing and terms of any additional financing; reconcile the differing IPO proceeds figures in the filing.
- Assess whether subsequent clinical data demonstrates reliable product accuracy and supports the intended regulatory pathway and commercialization timetable.
- Monitor remediation of the disclosed material weakness and effectiveness of financial reporting controls.
- Review dilution exposure: year-end warrants, options and other reserved shares, alongside potential future equity or convertible financings.